Highlights and Quick Summary
- Additional Paid In Capital for the quarter ending June 30, 2023 was $713 Million (a 4.35% increase compared to previous quarter)
- Year-over-year quarterly Additional Paid In Capital increased by 17.11%
- Annual Additional Paid In Capital for 2022 was $650 Million (a 8.81% increase from previous year)
- Annual Additional Paid In Capital for 2021 was $597 Million (a 41.6% increase from previous year)
- Annual Additional Paid In Capital for 2020 was $422 Million (a 6536.84% increase from previous year)
Visit stockrow.com/DYN
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Additional Paid In Capital of Dyne Therapeutics, Inc.
Most recent Additional Paid In Capitalof DYN including historical data for past 10 years.Interactive Chart of Additional Paid In Capital of Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc. Additional Paid In Capital for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2023 | $712.59 | $682.89 | – | – | – |
| 2022 | $649.5 | $608.47 | $604.57 | $601.44 | $649.5 |
| 2021 | $596.93 | $590.83 | $586.74 | $582.47 | $596.93 |
| 2020 | $421.57 | $417.37 | $0.0 | $0.0 | $421.57 |
| 2019 | $6.35 | $0.0 | – | – | $6.35 |
Business Profile of Dyne Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology